Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

MEBO Gut Microbiome Study
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Wednesday, May 30, 2012

The FDA Reform Act of 2012 passed today

May 30, 2012, WASHINGTON, DC--- The Food & Drug Administration Reform Act of 2012 (FDARA) was passed today by the U.S. House of Representatives. This bill contains numerous provisions that will enhance the review of promising new therapies for unmet medical needs, support the Rare Disease Program at FDA, and modernize the regulation of devices for use by small patient population.

The legislation contains the most comprehensive improvements to public policy for rare disease therapies since the Orphan Drug Act and also reauthorizes the user fees that support FDA review of new medical products.

“Today we join our allies throughout the health care community in thanking Chairman Upton and Ranking Member Waxman along with other House leaders for working together over many months to pass this momentous legislation,” said Peter L. Saltonstall, NORD President and C “It is ultimately patients and their families who will benefit most from the substantive policy in the Food and Drug Administration Reform Act of 2012. These reforms, once agreed to by both chambers of Congress and signed into law by the President, will herald even greater investment and innovation in the development of rare disease therapies.”

Read NORD's press release on the Senate Bill.


Post a Comment